STAT May 13, 2024
Hello! Today we learn whether AI might help hasten the development of n-of-1 therapies (hint: not yet), explore why the FDA hasn’t offered Orange Book guidance on drug-device combinations, and talk about CRISPR. A lot.
The need-to-know this morning
- AC Immune has sold global licensing rights to an experimental immunotherapy for Alzheimer’s disease to the Japanese drugmaker Takeda. AC Immune received $100 million from Takeda for the therapy, called ACI-24.060, and is eligible for another $2.1 billion in future payments.
- Merck reported negative results from an interim analysis of a Phase 3 study involving the use of its experimental anti-TIGIT antibody as an adjuvant treatment for patients with high-risk melanoma.
- Cancer drug developer OnKure is going public via a...
Today's Sponsors
Today's Sponsor